US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
SPCX
$158.96
▲+0.00%
JNJ
$256.03
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
META
$728.08
▲+0.00%
NVDA
$233.95
▲+0.00%
TSLA
$370.59
▲+0.00%
AMD
$633.91
▲+0.00%
SPCX
$158.96
▲+0.00%
JNJ
$256.03
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Samsung Bioepis
Samsung Bioepis Releases First Quarter 2025 US Biosimilar Market Report
January 16, 2025
From
Samsung Bioepis
Via
GlobeNewswire
Kyung-Ah Kim Named as President and Chief Executive Officer of Samsung Bioepis
November 27, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis’ Fourth Quarter 2024 US Biosimilar Market Report Highlights Challenges and Strategies for Biosimilar Adoption
October 10, 2024
From
Samsung Bioepis
Via
GlobeNewswire
FDA Approves Samsung Bioepis’ EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab)
July 22, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases Third Quarter 2024 US Biosimilar Market Report
July 11, 2024
From
Samsung Bioepis
Via
GlobeNewswire
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar to Stelara
July 01, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation
June 25, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases Second Quarter 2024 US Biosimilar Market Report
April 08, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)
April 05, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 09, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases First Quarter 2024 US Biosimilar Market Report
January 17, 2024
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara®
November 30, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
November 07, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Tickers
OGN
Samsung Bioepis Presents Phase 1 and 3 Clinical Results for SB16, a Proposed Biosimilar to Proliaⁱ (denosumab), at ASBMR 2023
October 15, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases Fourth Quarter 2023 US Biosimilar Market Report to Provide the Latest US Market Biosimilar Trends
October 10, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
September 11, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
August 01, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Tickers
OGN
Samsung Bioepis Releases its Second US Biosimilar Market Report
July 11, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases 2023 Sustainability Report
June 30, 2023
From
Samsung Bioepis
Via
GlobeNewswire
1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 24, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis to Present New Data for SB15, a proposed biosimilar to Eylea (aflibercept), at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 20, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Releases its First US Biosimilar Market Report, Providing Insights on Pricing Trends and Usage Across Molecules
April 17, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab), A Proposed Biosimilar to Stelara, at 2023 AAD Annual Meeting
March 17, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Samsung Bioepis Wins ‘Company of the Year, Asia-Pacific’ Award at the Global Generics & Biosimilars Awards 2022
November 03, 2022
From
Samsung Bioepis
Via
GlobeNewswire
